Cargando…
N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
Fibroproliferative diseases are responsible for 45% of deaths in the developed world. Curing organ fibrosis is essential for fibroproliferative diseases. Diabetic nephropathy is a common fibroproliferative disease of the kidney and is associated with multiorgan dysfunction. However, therapy to comba...
Autores principales: | Kanasaki, Keizo, Nagai, Takako, Nitta, Kyoko, Kitada, Munehiro, Koya, Daisuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995071/ https://www.ncbi.nlm.nih.gov/pubmed/24782774 http://dx.doi.org/10.3389/fphar.2014.00070 |
Ejemplares similares
-
N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition
por: Nagai, Takako, et al.
Publicado: (2014) -
Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors
por: Kanasaki, Megumi, et al.
Publicado: (2011) -
βklotho is essential for the anti‐endothelial mesenchymal transition effects of N‐acetyl‐seryl‐aspartyl‐lysyl‐proline
por: Gao, Rongfen, et al.
Publicado: (2019) -
Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis
por: Srivastava, Swayam Prakash, et al.
Publicado: (2016) -
Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen
por: Nitta, Kyoko, et al.
Publicado: (2016)